Core Laboratories stock slips after cautious earnings estimates

Published on 09/19/2026 at 21:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Core Laboratories stock closed at USD 11.23 on September 18, 2026, nearly 30 percent below its level at the start of the year. Zacks Research issued a more pessimistic CLB earnings estimate on September 17, 2026, adding caution to the outlook.

CLB, NL0015000CZ2, Illustration mit AI erstellt.

Core Laboratories N.V. stock (ISIN NL0015000CZ2) ended the last completed trading day at USD 11.23 on the New York Stock Exchange on September 18, 2026, down 1.49% from the prior close and almost 30% below its level at the start of 2026, according to data cited by MarketBeat.

Analyst estimate cut adds pressure

According to MarketBeat, Zacks Research issued a more pessimistic earnings estimate for Core Laboratories on September 17, 2026, signaling that at least one research house now expects weaker profitability in the coming quarters.

The same overview shows that Core Laboratories' stock was trading at USD 16.02 on January 1, 2026 and is now at USD 11.23, a decline of about 29.9% over the year to date, underscoring the pressure that the shares have been under in 2026.

Recent dividends and earnings context

As MarketBeat reports in its company calendar, Core Laboratories most recently reported earnings on July 29, 2026, and set a record date of August 10, 2026 for a dividend payable on August 31, 2026, indicating that the company continues to return cash to shareholders while navigating a weaker share price.

The same calendar lists an estimated next earnings date of October 28, 2026, giving investors a clear near term checkpoint at which new quarterly figures and guidance updates are likely to be published and could either confirm or challenge the currently more cautious earnings expectations.

Stock trades well below early-2026 level

Core Laboratories stock is trading significantly below its early 2026 level, with the price of USD 11.23 on September 18, 2026 compared with USD 16.02 on January 1, 2026, a year-to-date decline of 29.9% that highlights the extent of the reset in investor expectations described by MarketBeat.

For investors, the upcoming earnings release expected around October 28, 2026 and the reaction of analysts to those figures will be crucial in determining whether the current discounted valuation of Core Laboratories stock persists or begins to recover.

Core Laboratories stock and current price level

At the close on September 18, 2026 Core Laboratories stock traded at USD 11.23 on the New York Stock Exchange, with a daily loss of 1.49% from the previous session, placing the shares clearly below their January 1, 2026 level of USD 16.02 and reflecting the more cautious earnings outlook signaled by Zacks Research.